Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

Almira Chabi, Ying Zhang, Saheeda Jackson, Roger Cady, Christopher Lines, W. Joseph Herring, Kathryn M. Connor, David Michelson

Research output: Contribution to journalArticle

Abstract

Background: This study explored whether antagonism of orexin receptors might be an effective mechanism for migraine prevention. Methods:We conducted a randomized, double-blind, placebo-controlled, pilot trial. Patients experiencing four to 14 days with migraine during a one-month baseline period were randomized to the orexin receptor antagonist filorexant 10 mg nightly or placebo for three months. Efficacy was assessed by mean monthly migraine days (headache plus at least one associated migraine symptom) and headache days. Safety and tolerability were assessed by adverse event reports and laboratory tests. Results: Of 120 patients treated with filorexant and 115 treated with placebo, 97 (81%) and 101 (88%), respectively, completed the trial. There was no statistically significant difference between treatments for change from baseline in mean monthly migraine days (filorexant= -1.7, placebo= -1.3, difference= -0.4 (95% CI: -1.3, 0.4)) or headache days (filorexant= -1.7, placebo= -1.2, difference= -0.5 (95% CI: -1.4, 0.4)). Filorexant was generally well tolerated but was associated with a higher proportion of patients who reported adverse events than placebo (47% vs 37%), particularly somnolence (13% vs 4%). Conclusions: These data fail to provide evidence that antagonism of orexin receptors with filorexant, when administered at night, is effective for migraine prophylaxis.

Original languageEnglish (US)
Pages (from-to)379-388
Number of pages10
JournalCephalalgia
Volume35
Issue number5
DOIs
StatePublished - Apr 16 2015
Externally publishedYes

Fingerprint

Migraine Disorders
Randomized Controlled Trials
Placebos
Orexin Receptors
Headache
MK-6096
Orexin Receptor Antagonists
Safety

Keywords

  • Filorexant
  • migraine
  • MK-6096
  • orexin
  • prophylaxis

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

Chabi, A., Zhang, Y., Jackson, S., Cady, R., Lines, C., Herring, W. J., ... Michelson, D. (2015). Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia, 35(5), 379-388. https://doi.org/10.1177/0333102414544979

Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. / Chabi, Almira; Zhang, Ying; Jackson, Saheeda; Cady, Roger; Lines, Christopher; Herring, W. Joseph; Connor, Kathryn M.; Michelson, David.

In: Cephalalgia, Vol. 35, No. 5, 16.04.2015, p. 379-388.

Research output: Contribution to journalArticle

Chabi, A, Zhang, Y, Jackson, S, Cady, R, Lines, C, Herring, WJ, Connor, KM & Michelson, D 2015, 'Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis', Cephalalgia, vol. 35, no. 5, pp. 379-388. https://doi.org/10.1177/0333102414544979
Chabi, Almira ; Zhang, Ying ; Jackson, Saheeda ; Cady, Roger ; Lines, Christopher ; Herring, W. Joseph ; Connor, Kathryn M. ; Michelson, David. / Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. In: Cephalalgia. 2015 ; Vol. 35, No. 5. pp. 379-388.
@article{502f6beb7657454f904c5900c2321422,
title = "Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis",
abstract = "Background: This study explored whether antagonism of orexin receptors might be an effective mechanism for migraine prevention. Methods:We conducted a randomized, double-blind, placebo-controlled, pilot trial. Patients experiencing four to 14 days with migraine during a one-month baseline period were randomized to the orexin receptor antagonist filorexant 10 mg nightly or placebo for three months. Efficacy was assessed by mean monthly migraine days (headache plus at least one associated migraine symptom) and headache days. Safety and tolerability were assessed by adverse event reports and laboratory tests. Results: Of 120 patients treated with filorexant and 115 treated with placebo, 97 (81{\%}) and 101 (88{\%}), respectively, completed the trial. There was no statistically significant difference between treatments for change from baseline in mean monthly migraine days (filorexant= -1.7, placebo= -1.3, difference= -0.4 (95{\%} CI: -1.3, 0.4)) or headache days (filorexant= -1.7, placebo= -1.2, difference= -0.5 (95{\%} CI: -1.4, 0.4)). Filorexant was generally well tolerated but was associated with a higher proportion of patients who reported adverse events than placebo (47{\%} vs 37{\%}), particularly somnolence (13{\%} vs 4{\%}). Conclusions: These data fail to provide evidence that antagonism of orexin receptors with filorexant, when administered at night, is effective for migraine prophylaxis.",
keywords = "Filorexant, migraine, MK-6096, orexin, prophylaxis",
author = "Almira Chabi and Ying Zhang and Saheeda Jackson and Roger Cady and Christopher Lines and Herring, {W. Joseph} and Connor, {Kathryn M.} and David Michelson",
year = "2015",
month = "4",
day = "16",
doi = "10.1177/0333102414544979",
language = "English (US)",
volume = "35",
pages = "379--388",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

AU - Chabi, Almira

AU - Zhang, Ying

AU - Jackson, Saheeda

AU - Cady, Roger

AU - Lines, Christopher

AU - Herring, W. Joseph

AU - Connor, Kathryn M.

AU - Michelson, David

PY - 2015/4/16

Y1 - 2015/4/16

N2 - Background: This study explored whether antagonism of orexin receptors might be an effective mechanism for migraine prevention. Methods:We conducted a randomized, double-blind, placebo-controlled, pilot trial. Patients experiencing four to 14 days with migraine during a one-month baseline period were randomized to the orexin receptor antagonist filorexant 10 mg nightly or placebo for three months. Efficacy was assessed by mean monthly migraine days (headache plus at least one associated migraine symptom) and headache days. Safety and tolerability were assessed by adverse event reports and laboratory tests. Results: Of 120 patients treated with filorexant and 115 treated with placebo, 97 (81%) and 101 (88%), respectively, completed the trial. There was no statistically significant difference between treatments for change from baseline in mean monthly migraine days (filorexant= -1.7, placebo= -1.3, difference= -0.4 (95% CI: -1.3, 0.4)) or headache days (filorexant= -1.7, placebo= -1.2, difference= -0.5 (95% CI: -1.4, 0.4)). Filorexant was generally well tolerated but was associated with a higher proportion of patients who reported adverse events than placebo (47% vs 37%), particularly somnolence (13% vs 4%). Conclusions: These data fail to provide evidence that antagonism of orexin receptors with filorexant, when administered at night, is effective for migraine prophylaxis.

AB - Background: This study explored whether antagonism of orexin receptors might be an effective mechanism for migraine prevention. Methods:We conducted a randomized, double-blind, placebo-controlled, pilot trial. Patients experiencing four to 14 days with migraine during a one-month baseline period were randomized to the orexin receptor antagonist filorexant 10 mg nightly or placebo for three months. Efficacy was assessed by mean monthly migraine days (headache plus at least one associated migraine symptom) and headache days. Safety and tolerability were assessed by adverse event reports and laboratory tests. Results: Of 120 patients treated with filorexant and 115 treated with placebo, 97 (81%) and 101 (88%), respectively, completed the trial. There was no statistically significant difference between treatments for change from baseline in mean monthly migraine days (filorexant= -1.7, placebo= -1.3, difference= -0.4 (95% CI: -1.3, 0.4)) or headache days (filorexant= -1.7, placebo= -1.2, difference= -0.5 (95% CI: -1.4, 0.4)). Filorexant was generally well tolerated but was associated with a higher proportion of patients who reported adverse events than placebo (47% vs 37%), particularly somnolence (13% vs 4%). Conclusions: These data fail to provide evidence that antagonism of orexin receptors with filorexant, when administered at night, is effective for migraine prophylaxis.

KW - Filorexant

KW - migraine

KW - MK-6096

KW - orexin

KW - prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84924765911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924765911&partnerID=8YFLogxK

U2 - 10.1177/0333102414544979

DO - 10.1177/0333102414544979

M3 - Article

C2 - 25106663

AN - SCOPUS:84924765911

VL - 35

SP - 379

EP - 388

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 5

ER -